Sei Investments Co. Grows Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Sei Investments Co. boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 10.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 70,384 shares of the biotechnology company’s stock after buying an additional 6,411 shares during the quarter. Sei Investments Co. owned 0.11% of Blueprint Medicines worth $6,139,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Torray Investment Partners LLC grew its position in shares of Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock valued at $1,439,000 after acquiring an additional 186 shares during the period. Franklin Resources Inc. lifted its position in Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after purchasing an additional 265 shares in the last quarter. Quarry LP bought a new stake in Blueprint Medicines during the third quarter valued at about $32,000. Van ECK Associates Corp raised its stake in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after buying an additional 363 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in shares of Blueprint Medicines by 31.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,650 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 399 shares during the period.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the sale, the insider now directly owns 14,967 shares in the company, valued at $1,496,700. This represents a 13.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,608 shares of company stock valued at $3,319,587. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Down 0.2 %

Shares of NASDAQ:BPMC opened at $88.51 on Tuesday. The business’s 50 day moving average is $97.70 and its 200 day moving average is $94.07. The stock has a market cap of $5.66 billion, a P/E ratio of -81.95 and a beta of 0.58. Blueprint Medicines Co. has a 52-week low of $80.68 and a 52-week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Sell-side analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BPMC. Wedbush reaffirmed an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Wolfe Research began coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. increased their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Morgan Stanley initiated coverage on Blueprint Medicines in a report on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price target for the company. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.